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Introduction
These guidelines are based upon most recent and updated
evidence and they are adapted to an European problematic by
an expert view of the problem. These guidelines are not
intended to be a meta-analysis or a systematic review. They
follow the previous guidelines published in 2006 [1].
Identiﬁcation of preterm labor
Several biochemical and biophysical markers have been
proposed for the identiﬁcation of patients at risk for
spontaneous preterm delivery, in both patients with threa-
tened preterm labor and asymptomatic ones, with the hope
that interventions could prevent preterm delivery [2–4]. There
is now compelling evidence that examination of the cervix
with ultrasound is superior to vaginal digital examination [5]
and in patients presenting with preterm labor can assist in
determining the risk for preterm delivery before 34 weeks. In
general, the shorter the cervix, the higher the risk for preterm
delivery and vice versa [2,6]. Transvaginal cervical sonogra-
phy is a good method to assess the risk of preterm delivery in
patients presenting with preterm labor, low-risk asymptomatic
patients, and patients at high risk for preterm delivery [7,8].
Furthermore, in patients with a long cervical length
(43.0 cm), the likelihood of preterm delivery is low and,
therefore, avoiding aggressive intervention in the setting of
premature labor may be justiﬁed [1,2,9]. In contrast, patients
who have a short cervix would have a higher rate of preterm
delivery and may beneﬁt from targeted interventions (i.e.
steroid administration and transfer to a centre with a newborn
special intensive care unit) [10].
A cervical length of 25 mm or less had a sensitivity,
speciﬁcity, positive predictive value, and negative predictive
value of 76%, 68%, 20%, and 96%, respectively, to identify
preterm singleton birth at less than 34 weeks of gestation [8].
It should be also noted that endovaginal sonographic
examination of the uterine cervix in women with preterm
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The evidence provided by several studies suggests that the
assessment of the risk of preterm delivery in patients with a
previous history of preterm birth or mid-trimester pregnancy
loss require a longer cervix than those without such a
history [6].
The assessment of the frequency of uterine contractions
has been proposed to identify those at risk for preterm delivery
in both asymptomatic and symptomatic pregnant patients.
The rationale for this is that increased frequency of uterine
contractions leads to preterm delivery. However, the results of
randomized clinical trials have indicated that ambulatory
uterine monitoring has not reduced the rate of preterm
delivery [12].
A growing body of evidence indicates that a positive fetal
ﬁbronectin (fFN) test in cervical and/or vaginal ﬂuids is
associated with preterm delivery both in patients with
threatened preterm labor and in symptomatic patients. A
negative fFN test identiﬁes patients at very low risk [4,6,13].
A positive fFN test and/or increased cytokine concentra-
tions in cervicovaginal ﬂuid increase the predictive value of
cervical ultrasonography to identify patients at risk for preterm
delivery [2,14,15].
Actim Partus (phosphorylated insulin-like growth factor
binding protein 1 – pIGFBP-1) test can be used for estimating
the risk of preterm delivery. The test detects pIGFBP-1 in
cervical secretions. Similarly to the fFN test, the Actim Partus
test has been shown to efﬁciently rule out the risk of preterm
or imminent delivery. An advantage compared to the fFN test
is that the Actim Partus test is not affected by seminal ﬂuid,
and can thus also be used on patients with recent intercourse
[16]. However, the test has not been consistently associated to
cervical length and scientiﬁc evidence is still lacking on its
comparison with fFN data.
In a recent systematic review, it has been found that
cervicovaginal fFN has limited accuracy in predicting sponta-
neous preterm birth in both asymptomatic and symptomatic
women with multiple pregnancies because the likelihood
ratios for positive and negative test results generated only
minimal to moderate changes in the pretest probabilities of
preterm birth. The test was most accurate in predicting
spontaneous preterm birth before 32 weeks’ gestation in
asymptomatic women with multiple or twin pregnancies, and
spontaneous preterm birth within 7 days of testing in women
with twin pregnancies and threatened preterm labor [13].
This meta-analysis suggests that only 1.6% of women with
twin pregnancies and threatened preterm labor who test
negative for cervicovaginal fFN will deliver in the next week.
This ﬁnding could be clinically important because these
women could be cared for at a primary care center rather than
transferred to a tertiary care center.
However, the lack of effectiveness of clinical interventions
may be due to: (1) the limitations of the current tests for the
diagnosis; (2) inadequate interventions; (3) the timing of the
interventions; (4) an incorrect conceptual frame work. Preterm
labor is one of the great obstetrical syndromes together with
small for gestational age (SGA), preeclampsia, preterm
premature rupture of membranes (PROM) and fetal death
[10]. Thus, preterm labor has multiple etiologies, is chronic in
nature and is frequently associated with fetal disease, and the
clinical manifestations in both the mother and the fetus may be
adaptiveinnature.Moreover,thesemanifestationsmaydepend
on the maternal and fetal gene-environment interaction.
Main points
Biophysical markers, biochemical markers, or a combina-
tion of both may better identify patients at risk for preterm
delivery. Ultrasonography to determine cervical length, fFN
testing or a combination of both is the most useful tools in
determining women at high risk for preterm labor.
However, their clinical usefulness may rest primarily with
their negative predictive value given the lack of proven
treatment options to prevent spontaneous preterm labor
(SPB). Bearing in mind the excellent negative predictive
value of such tests (when ﬁbronectin is negative and
cervical length by ultrasound is 42.5 cm) we recommend
that tocolytic therapy and steroid prophylaxis should be
withheld.
Diagnosis of preterm premature rupture of
membrane
Approximately, 8–10% of term pregnancies will experience
spontaneous PPROM prior to the onset of uterine activity.
Preterm PROM-deﬁned as PPROM, prior to 37 weeks of
gestation, complicates 2–4% of all singleton and 7–20% of
twin pregnancies [17–20].
A number of risk factors for spontaneous PPROM have been
identiﬁed. Intra-amniotic infection and decidual hemorrhage
(placental abruption) occurring remote from term, for example,
may release proteases into the choriodecidual tissues and
amniotic ﬂuid, leading to rupture of membranes. Indeed,
placentalabruptionisseenin4–12%ofpregnanciescomplicated
byPPROM,andismorecommoninpregnanciescomplicatedby
PPROM prior to 28 weeks of gestation. However, whether it is
the cause of PPROM or a consequence of acute uterine
decompression is not known [20]. Invasive uterine procedures
performedduringpregnancy(suchasamniocentesis,cordocent-
esis, chorionic villus sampling, fetoscopy, and cervical cerclage)
can damage the membranes, causing them to leak, but these are
rare causes of PPROM [20,21].
Rupture of the membranes typically presents as a large
gush of clear vaginal ﬂuid or as a steady trickle. The
differential diagnosis includes leakage of urine (urinary
incontinence); excessive vaginal discharge, such as physiologic
discharge or bacterial vaginosis, and cervical mucus (show) as
a sign of impending labor [21,22]. Latency refers to the
interval between rupture of the membranes and the onset of
labor. A number of factors are known to affect the latency
period, including: gestational age, degree of oligohydramnios,
sonographic myometrial thickness, number of fetuses, preg-
nancy complications such as intra-amniotic infection, placen-
tal abruption, or active labor [21,22].
Maternal and fetal infection is the second major complica-
tion consecutive to PPROM, as chorioamnionitis complicates
10–36% of PPROM. Early and accurate diagnosis is necessary
to appropriately manage patients with PROM and to limit
unnecessary intervention in patients without PROM [19].
Early and accurate diagnosis of PPROM would allow for
gestational age-speciﬁc obstetric interventions designed to
optimize perinatal outcome and minimize serious complica-
tions, such as cord prolapse and infectious morbidity
(chorioamnionitis, neonatal sepsis) [22–25]. Conversely, a
false-positive diagnosis of PPROM may lead to unnecessary
obstetric intervention, including hospitalization, administra-
tion of antibiotics and corticosteroids, and even induction of
labor.
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with heavy watery vaginal discharge or when clear ﬂuid can be
seen leaking from the cervical os. However, recent data
suggest that in 47% of the cases, clinicians are uncertain
regarding the diagnosis of PPROM based on clinical
examination by sterile speculum examination and patient
history alone [26]. Diagnosis is indeed difﬁcult when leakage
of ﬂuid is tiny and/or intermittent and/or ultrasound
examination shows a normal to low index of amniotic ﬂuid.
In these cases, noninvasive biochemical tests can help in
diagnosing PPROM.
‘Classic’ tests are represented by an alkaline pH of the
cervicovaginal discharge, which is typically demonstrated by
seeing whether discharge turns yellow nitrazine paper to blue
(nitrazine test); and/or microscopic ferning of the cervicova-
ginal discharge on drying. Evidence of diminished amniotic
ﬂuid volume alone cannot conﬁrm the diagnosis, but may
help to suggest it in the appropriate clinical setting [21,27,28].
Efforts to be able to conﬁrm chorioamniotic membrane
rupture with minute amounts of amniotic ﬂuid have recently
led to the development of the absorbent pad (AmnioSense).
This 12 cm64 cm pad has a central strip that changes color
with ﬂuid with a pH 45.2 [29,30]. After contact with urine,
the strip reverts to its original color when dry. This is due to
the detachment of conjugate-based nitrazine molecules by the
urine ammonium ions [29]. AmnioSense has undergone
cytotoxicity and skin irritation and sensitization testing. The
two studies of the absorbent pad currently available [29,30]
suggest that a negative AmnioSense result indicates intact
membranes in term and preterm gestations in 99% of cases. It
remains unknown whether potential confounding substances
such as semen, blood, or meconium may be distinguished
from amniotic ﬂuid by the AmnioSense pad test [31]. The
effects of cervicitis, vaginitis (bacterial vaginosis), and
contamination with blood, urine, semen, or antiseptic agents
on traditional nitrazine or pH-based technologies has been
widely documented and shown to lead to high false-positive
rates [19,32–34].
The fern test refers to microscopic crystallization of
amniotic ﬂuid on drying of the vaginally collected sample. It
has been shown to give false-positive results due to
ﬁngerprints or contamination with semen and cervical mucus
as well as false negative results due to the use of dry swabs or
contamination with blood [27,34,35]. More speciﬁcally, de
Haan et al. showed false-positive and false-negative rates of
11.8% and 2.0%, respectively, for women in labor tested for
amniotic ﬂuid crystallization but for women not in labor, rates
rise up to 21.2.% and 40.6%, respectively [34].
All of the abovementioned clinical methods have limita-
tions in terms of diagnostic accuracy, cost and technical ease.
Moreover, such tests become progressively less accurate when
more than 1 h has elapsed after the membranes have
ruptured. As such, the sensitivity and speciﬁcity for pH in
diagnosing ROM ranges from 90 to 97%, and 16 to 70%,
respectively, and the sensitivity and speciﬁcity for the fern test
in diagnosing ROM ranges from 51 to 98% and 70 to 88%,
respectively.
Because of the limitations with the current standard for the
diagnosis of PPROM (namely, clinical assessment of pooling,
nitrazine, and/or ferning), investigators have long been
searching for an alternative and more objective test. Such
tests are based primarily on the identiﬁcation in the
cervicovaginal discharge of one or more biochemical markers
that are present in the setting of ROM, but absent in women
with intact membranes. Several such markers have been
studied, including a-fetoprotein (AFP), fFN, IGFBP-1,
prolactin, diamine oxidase activity, b-subunit of human
chorionic gonadotropin (b-hCG) and placental a-microglo-
bulin-1 in order to identify PROM [36–41]. However, results
using such test have been variable (Table I). Diamine/oxidase
is one of the most efﬁcient tests with a reported sensitivity of
87.3–100% and speciﬁcity of 98–100%, but lecture based on
radio-immunoassay need speciﬁc and costing equipment [22].
To reduce false-positive rate, the test should identify a
protein present in high quantity in amniotic ﬂuid compared
with other physiological ﬂuid such as maternal blood, vaginal
secretion, and seminal ﬂuid.
IGFPB-1 and placental alpha microglobulin-1 (PAMG-1)
are fulﬁlling these criteria and can be detected with
respectively the Actim Prom
TM test and the most recently
developed Amnisure
1 ROM test [38,39,42,43].
IGFBP-1 is a 28 kDa protein produced by fetal liver and
decidua. The IGFBP-1 protein is present in amniotic ﬂuid in
large concentrations, but absent from seminal plasma, urine,
and maternal blood [42]. Concentration in amniotic ﬂuid
increases with gestational age from 27 ng/ml in early
pregnancy to 145,000 ng/ml at term, whereas maternal blood
concentration varies between 58 and 600 ng/ml. Actim
Prom
TM Test (Medix Biochemica, Kauniainen, Finland)
has a lower detection limit of 25 ng/ml. The result is either
positive (IGFBP-1 is present; threshold exceed 30 mg/l), or
negative (IGFBP-1 less than 30 mg/l) obtained within 10–
15 min of performing the test. Its sensitivity varies from 74 to
100% and speciﬁcity from 77 to 98.2% [38,42,44–46]. So the
test is speciﬁc to amniotic ﬂuid and sensitive enough to help to
diagnose also micro ruptures. This test has been in wide
clinical use for over a decade.
PAMG-1 is a 34 kDa glycoprotein synthesized by the
decidua. Amniotic ﬂuid concentration ranges from 2000 to
25000 ng/ml and maternal blood concentration from 0.5 to 2
ng/ml.
Amnisure
1 ROM Test (AmniSure
1 International LLC,
Boston, MA) has a lower detection limit of 5 ng/ml with a
sensitivity close to 99% and speciﬁcity varying between 87.5
and 100% [39,43,47]. Moreover, some investigators have
proposed that concentrations of PAMG-1 in cervicovaginal
ﬂuid in patients without clinical proof of ROM may represent
evidence of microleakage of amniotic ﬂuid. Amnisure ROM
test was performed in patients without evidence of clinical
ROM. Patients in labor without clinical ROM, but with a
positive Amnisure test had a signiﬁcantly shorter admission-
to-delivery interval than patients in labor without clinical
ROM with a negative Amnisure ROM test [47,48]. Lee et al.
demonstrated that the Amnisure test has a better diagnostic
accuracy than combined use of nitrazine, fern and pooling, as
well as the nitrazine test alone.
As amniotic ﬂuid sample collected in the vagina is
systematically contaminated with vaginal discharge, the
detection limit is an important parameter to consider for the
performance of the test. The detection limit of PAMG-1 with
Amnisure ROM test (5 ng/ml) is lower than the limit
detection of IGFBP-1 with Actim PROM test (25 ng/ml).
[22,38,49]. Recent investigations into the effect of high blood
admixture to the patient sample on the PAMG-1 test have
shown that blood admixtures as high as 50% do not interfere
with the PAMG-1 test [50]. Semen and urine do not interfere
with PAMG-1 test either, as both substances do not contain
PAMG-1 protein.
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severe limitation for investigating new diagnostic tests. Ideally,
a gold standard test would be an amnio-dye test consisting of
amniocentesis for instillation of indigo carmine in amniotic
cavity and research for leakage of blue-stained ﬂuid into the
vagina within 20–30 min [51]. This method, however,
presents the disadvantage of being invasive and carries risks
of ROM and infectious complications. Only PAMG-1 test has
been compared to amnio-dye test. Preliminary results of this
study were published recently and indicate that PAMG-1 test
is as reliable as amnio-dye test in diagnosing ROM [51].
A limited number of quality studies and the limited
number of cases with preterm birth per study seriously
constrain the conclusions regarding the reliability of different
ROM diagnostic methods. As spontaneous preterm birth has
low prevalence, particularly for important outcomes such as
birth before 34 weeks’ gestation or birth within 48 h of
presentation, the small absolute numbers of affected cases
introduced imprecision by increasing variance. All that said,
the relative performances of the diagnostic tests used in the
various studies, regardless of the gold standard to which they
were compared, have continuously suggested that the test
based on PAMG-1 detection is more reliable and noninvasive
than other methodologies [26,38,39,43,52].
Main points
1. PPROM complicates 2–20% of all deliveries and it is
associated with 18–20% of perinatal deaths. Management
options include admission to the hospital and administra-
tion of antenatal corticosteroids. Amniocentesis to exclude
intra-amniotic infection and/or broad-spectrum antibiotics
prophylaxis are further options.
2. The clinical signs of PPROM documented on sterile
speculum examination are copious isualpooling of ﬂuid in
the vagina or leakage of ﬂuid from the cervical os.
Complementary evidence includes an alkaline pH of
cervicovaginal discharge, and/or microscoping ferning of
the cervicovaginal discharge on drying.
3. The clinical signs of PPROM become progressively less
accurate when more than 1 h has elapsed after membrane
rupture. Evaluation of ferning, nitrazine, and/or ultra-
sound has shown that they add little, if anything, to
speculum examination alone and that none of them are as
accurate as the test based on biochemical markers.
Accordingly, we believe that there is little to merit their
use in modern practice.
4. Investigators search for a test based primarily on the
identiﬁcation in the cervicovaginal discharge of 1 or more
biochemical markers that are present with ROM, but
absent in women with intact membranes [22,30]. Bio-
chemical markers are better than the traditional methods,
as they are speciﬁc to proteins found in amniotic ﬂuid.
Thus they are not affected by most contaminating
substances and enable a fast and reliable bedside
diagnosis.
5. PAMG-1 test is most useful tool in determining women at
high risk for premature rupture of fetal membranes. The
rapid strip test based on PAMG-1 seems to be the more
Table I. Performance of noninvasive tests to diagnose rupture of the fetal membranes.
Test/Reference Name of test Cutoff Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
Nitrazine (pH) – Positive/negative 90–97 16–70 63–75 80–93
Ferning and/or
pooling
– Positive/negative 51–98 70–88 84–93 87–97
AFP ROM Check
1
(Adeza
Biomedical
Corp., Sunnyvale,
CA)
430 mg/l 90–94 95–100 94–100 91–94
Fetal ﬁbronectin – 450 ng/ml 97–98 70–97 74–93 98–100
IGBP-1 PROM-TEST
1
(Medix
Biochimica,
Kauinianen,
Finland) AMNI
Check
1 (MAST
Diagnostica,
Reinﬁeld, Ger-
many)
43 mg/l 74–97 74–98 73–97 56–95
Prolactin – 430–50 mIU/ml 70–95 76–78 72–84 75–93
Diamine oxidase 425 mIU/test 83 90–100 100 89
b-hCG – 440–65 mIU/ml 68–95 70–95 73–91 78–97
Urea and creatinine – 40.12–0.6 mg/dl 90–100 87–100 94–100 91–100
AmnioSense
Absorbent pad
pH 4 5.2 98.3 70 65–70 98
Lactate Lac test
1  4.5 mmol/l 79–86 88–92 88–92 78–87
PAMG-1 AmniSure
1 ROM
Test (AmniSure
1
International
LLC, Cambridge,
MA)
45.0 ng/ml 98–99 88–100 98–100 91–99
AFP, alpha-fetoprotein; b-hCG, beta-subunit of human chorionic gonadotropin; IGFBP-1, insulin-like growth factor binding protein 1; NPV,
negative predictive value; PAMG-1, placental alpha-microglobulin 1; PPV, positive predictive value (modiﬁed from reference [22] and [31]).
662 G. D. Di Renzo et al.accurate bedside test compared with others [26,38,49,
51,52].
Preventive tools
Cervical cerclage
The use of cervical cerclage has been one of the preventive
strategies used for many years; however, there are no studies
that show overall evidence except in very speciﬁc cases [53–
55]. It is clear that the use of cerclage based on a short cervix
has any effect on prevention of prematurity [54,56]. The
literature shows evidence that cerclage provides clear and
proven beneﬁts only in circumstances diagnosed with ‘cervical
incompetence’. In cases of a previous history of three or more
late abortions, or three or more preterm delivery, cerclage
performed in the ﬁrst half of pregnancy in patients with a
single fetus shows a statistically signiﬁcant beneﬁcial effect
[57–59]. Cerclage may have a beneﬁcial effect in preventing
preterm delivery when there is a history of preterm labor and
an objective decrease in cervical length or increase cervix
dilatation in non-symptomatic patients [55,60–62]. In cases
with uterine abnormalities, cerclage has failed to show
evidence of improvement in perinatal results [58]. Also, in
cases of twin pregnancies cerclage has even shown a
deleterious effect (increasing paradoxically the rate of preterm
delivery), therefore it is not recommended in these settings
[55,61,63]; nor it has been proved effective in cases with
previous cervical conization [64]. In cases with advanced
cervical dilation and uterine contractions, the use of emer-
gency cerclage associated with the administration of tocolytic
agents has shown controversial effects [55,60,65,66]. There
are no differences between the Shirodkar or MacDonald type
of cerclage [67,68]. The cerclage should be performed in
absence of contraindications such as placenta previa, cervical
or vaginal infections, amniotic infection, uterine bleeding,
fetal malformations, fetal death or distress or alterations of the
amount of amniotic ﬂuid (polyhydramnios or oligohydram-
nios), PROM, or maternal contraindications [69]. The most
common complication of cerclage is PROM and amniotic
infection and therefore appropriate controls of infections
should be carried out [70]. Likewise, at the time of delivery,
the presence of a previous cerclage has been associated to
increased cervical dystocia. It is important to observe that a
marker of appropriate placement of the cerclage is the distance
from cerclage and the internal cervical os, as measured by
ultrasound. A measure of 10 mm represents a good surgical
result [71,72].
Cervical pessary
Many years ago, the cervical pessary was used for cervical
incompetence with very inconsistent results [73]. In recent
years, it has been considered the preventive effect on preterm
delivery of placing a cervical pessary in non-symptomatic
patients, with singleton pregnancy and a short cervix (less
than 25 mm, at 20–24 weeks gestation as risk marker),
without prior cervical incompetence [74,75]. Various studies
show signiﬁcant risk reduction without increasing the rate of
vaginal infections [76,77]. Only a properly designed, pro-
spective, randomized study has conﬁrmed these results (28 vs
5%), so this preventive strategy must be analyzed with caution
[76,77]. Similar studies in patients with twins are being
conducted, with no conclusive results. Therefore, these
guidelines can only be intended as source of information of
this possibility and recommended for use only in research
protocols.
Progestogens use in pregnancy
The knowledge that an increased activity of endogenous
progesterone (P4) was a necessary event for the development
and the maintenance of pregnancy dates back to the ﬁrst half
of the last century [78]. Around the 60s we acquired the idea
that a withdrawal of endogenous P4 was related to the onset of
labor [79] even preterm [80]. Since then, P4 and related
synthetic compounds such as 17 a-hydroxy progesterone
caproate (17 OHP-C) as well as other progestogens have been
tested in clinical trials to prevent the challenging phenomenon
of preterm birth (PTB).
In one of the ﬁrst meta-analyses ever published about
perinatal interventions, it was demonstrated that 17 OHP-C
treatment was associated with a reduced rate of PTB (both
preterm delivery less than 37 weeks and babies weighting less
than 2500 g) in respect with placebo or no intervention [81].
Surprisingly, such achievement was not implemented into
clinical practice, nor scientiﬁc societies endorsed such
conclusions producing recommendations. The William’s
Obstetrics textbook 21st edition released in 2001 did not
mention progesterone among interventions able to prevent
PTB and stated (p. 270): ‘Progesterone administration to
pregnant women does not... arrest or prevent preterm labor’
[82]. Clinical and experimental studies re-started in the years
2000 [83]. Now, an almost equal number of randomised
controlled trials (RCTs) and meta-analyses is available while
several trials are still being planned or are ongoing.
The vast majority of such clinical trials were performed
with diverse formulations of either P4 or 17 OHP-C [84]. P4
has been administered through daily vaginal route by using
two different pharmaceutical preparations, i.e. 8% gel or 100–
400 mg micronized hormone. On the other hand, 17 OHP-C
has been administered through intramuscular injection, by
using doses ranging 250–682 mg/week, with drug dissolved in
castor or ethyl oil. Given the different biological actions of P4
and 17 OHP-C [85] and considering that we still ignore the
mechanism(s) of action of such treatments it seems difﬁcult at
present to put together the results of all these RCTs under the
umbrella of ‘progesterone treatment’ [86].
A further source of heterogeneity which refrains from
summarizing published data into guidelines is represented by
the inclusion criteria utilized in the different studies [87]. The
most part of randomized subjects is represented by women
with a history of at least one previous spontaneous PTB or
by multiple pregnancies. However, asymptomatic mid-second
trimester women with a very short cervix as well as
third-trimester patients having had a successful treatment of
a preterm labor episode were also admitted to ‘progesterone’
supplementation.
Micronized progesterone capsules (200 mg vaginally
daily) were used in the trial of P4 for asymptomatic women
with a very short cervix (less than 15 mm), and appeared to
be effective for such an indication [6]. Whether the
differences seen in efﬁcacy of the recently studied vaginal
preparations reﬂects differences in dosages (100 mg versus
200 mg), variation in absorption and bioavailability with
different preparations (gel versus capsule versus supposi-
tory), or differences in study populations remain to be
elucidated [88]. Supplemental 17 OHPC treatment does
not beneﬁt women with short cervix and previous preterm
birth submitted to cervical cerclage for suspected cervical
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receive a cerclage, 17 OHPC reduced perinatal mortality
[89].
Neither progesterone nor 17 OHPC has been studied as a
preventive agent for asymptomatic women with a positive
cervicovaginal fFN screen result or as therapeutic agent in
PPROM. Both P4 and 17 OHPC has been proven effective in
the tertiary prophylaxis of preterm birth after tocolysis
[86,90].
Concerning safety issues pertaining the prolonged use of
P4 or OHP-C, neither progesterone nor 17-OHP-C consis-
tently adversely affected maternal weight, embryo-fetal
viability, or caused malformations in non-clinical studies
conducted in mice, rats, rabbits, guinea pigs, horses, or non-
human primates. There is a signal for embryo–fetal toxicity
associated with 17-OHP-C in the two largest clinical trials
conducted to date; there is also a signal for embryo–fetal
toxicity with 17-OHP-C in rhesus monkeys and possibly one
in rodent species. The relationship between these signals is
unclear given the absence of state-of-the-art reproductive
toxicology studies and human pharmacokinetic studies [91].
The effects of 17-OHP-C upon pregnancy in experimental
animals have been studied in rats, rabbits, mice, and monkeys.
Earlier studies found no evidence of androgenic or glucorti-
coid activity and no virilising effects on female fetuses [92–
96]. It is worth noting that the synthetic 17-OHP-C and
natural progesterone are not similar molecules and have
different activities in a number of respects including their
effects on the myometrium [85,97–100]. Natural progester-
one has documented properties of inhibiting uterine contrac-
tions [85,98,100], whereas 17-OHP-C seems to have no effect
on uterine contractions [85,99]. In addition, natural proges-
terone has an established safety proﬁle in the ﬁrst trimester of
pregnancy from more than 11 years of continued and ongoing
use in infertility as daily progesterone supplementation and
replacement in IVF cycles [101]. Furthermore, in a recent
very large preterm birth prevention study of singleton
pregnancies, no cases of miscarriage associated with the use
of micronized natural progesterone were observed [102]. On
the other hand, 17-OHP-C is associated with an increase in
resorption (miscarriage) in pregnant rats [96], total embryo-
lethality in pregnant rhesus monkeys [103], a signal for a 30%
increase in miscarriage in a meta-analysis of 17-OHP-C
clinical studies [81], as well as an imbalance in miscarriage
associated with 17-OHP-C in the largest placebo controlled
randomized trial published to date [83]. In a study by
Rebarber et al. [104], patients who received prophylactic
treatment with 17-OHP-C had a higher incidence of gesta-
tional diabetes (odds ratio 2.9 [95% CI: 2.1–4.1]) than those
who were not treated. The latter study suggests that treatment
with 17-OHP-C may be associated also with increased
maternal morbidity that is an additional safety ﬂag.
Main points
Considering all of the above reported limitations and based on
the primary studies published to date, the following state-
ments could be actually advised.
1. In asymptomatic women presenting with prior history of
PTB, the early prophylaxis with either P4 microionized or
17 OHP-C demonstrated to be efﬁcacious in preventing
recurrence [83,98,102,105–108]. In the above reported
conditions, we advice to implement prophylaxis (200 mg
vaginal P4 or 250 mg/weekly i.m. 17 OHP-C) since early
second trimester, in such condition.
2. In single pregnant, nulliparous women where a silent
cervical shortening (15 mm) could be detected with trans-
vaginal ultrasound both microionized P4 and 17 OHP-C
have proven to be able to reduce PTB, in respect with
placebo [6,89,109]. Two good quality studies performed
in few subjects support this intervention which, however,
requires further conﬁrmation before being recommended
in the clinical practice.
3. In single pregnant, nulliparous women successfully treated
for a preterm labor episode microionized P4 reduced the
rate of PTB in respect with no intervention/placebo
[90,110]. The use of progestogens (400 mg/daily vaginal
microionized P4 or 375 mg/twice a week i.m. 17 OHP-C)
as a maintenance tocolysis, however, requires further
studies before being recommended for the tertiary
prophylaxis of PTB.
4. In multiple pregnancies, either twins or triplets, neither
microionized P4 nor 17 OHP-C is able to prevent PTB
[111–114]. Data are consistent and number of women
studied enough to advice not to use progestogens in such
condition [115].
5. Maternal safety of either microionised P4 or 17 OHP-C
administration has been reported in different trials [97].
Neonatal safety has been evaluated in only one trial
where mothers have been treated with 17 OHP-C [116].
No effects of general health status, external genitalia,
and psychomotor development have been reported at
follow-up. However, there is concern about the increase
in fetal death in mid-trimester and the higher incidence
of gestational diabetes linked to 17-OHP-C. Since the
paucity of data, ongoing trials are encouraged to include
neonates follow-up in their design. Moreover, in view of
the widespread use of progestogens in pregnant women,
physicians should be aware of these facts for proper
informed recommendation about the use of 17-OHP-C
and post-marketing surveillance has to be advised.
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